title: The IL-1β Receptor Antagonist SER140 Postpones the Onset of Diabetes in Female Nonobese Diabetic Mice.
abstract: The cytokine interleukin-1β (IL-1β) is known to stimulate proinflammatory immune responses and impair β-cell function and viability, all critical events in the pathogenesis of type 1 diabetes (T1D). Here we evaluate the effect of SER140, a small peptide IL-1β receptor antagonist, on diabetes progression and cellular pancreatic changes in female nonobese diabetic (NOD) mice. Eight weeks of treatment with SER140 reduced the incidence of diabetes by more than 50% compared with vehicle, decreased blood glucose, and increased plasma insulin. Additionally, SER140 changed the endocrine and immune cells dynamics in the NOD mouse pancreas. Together, the data suggest that SER140 treatment postpones the onset of diabetes in female NOD mice by interfering with IL-1β activated pathways.
authors.affiliation: Gubra ApS, Agern Alle 1, 2970 Hørsholm, Denmark.
authors.forename: Helena
authors.initials: H
authors.lastname: Cucak
authors.affiliation: Gubra ApS, Agern Alle 1, 2970 Hørsholm, Denmark.
authors.forename: Gitte
authors.initials: G
authors.lastname: Hansen
authors.affiliation: Gubra ApS, Agern Alle 1, 2970 Hørsholm, Denmark.
authors.forename: Niels
authors.initials: N
authors.lastname: Vrang
authors.affiliation: Serodus ASA, Gaustadalléen 21, 0349 Oslo, Norway.
authors.forename: Torben
authors.initials: T
authors.lastname: Skarsfeldt
authors.affiliation: Serodus ASA, Gaustadalléen 21, 0349 Oslo, Norway.
authors.forename: Eva
authors.initials: E
authors.lastname: Steiness
authors.affiliation: Gubra ApS, Agern Alle 1, 2970 Hørsholm, Denmark.
authors.forename: Jacob
authors.initials: J
authors.lastname: Jelsing
mesh_terms: D000818:Animals; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D003920:Diabetes Mellitus / Q000097:blood / Q000473:pathology / Q000517:prevention & control*; D005260:Female; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007328:Insulin / Q000097:blood; D050417:Insulin-Secreting Cells / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D053583:Interleukin-1beta / Q000378:metabolism*; D016688:Mice, Inbred NOD; D009842:Oligopeptides / Q000494:pharmacology; D010455:Peptides / Q000494:pharmacology*; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D013997:Time Factors
chemical_list: D015415:Biomarkers; D001786:Blood Glucose; D007004:Hypoglycemic Agents; C587672:IL1B protein, mouse; D007328:Insulin; D053583:Interleukin-1beta; D009842:Oligopeptides; D010455:Peptides; D017472:Receptors, Interleukin-1; C000591539:ilantide